AUTHORS
Xi Jia, Pengcheng SHI2, Qifa Liu, MD3, Xi Xu4
AFFILIATIONS
1 Nanfang Hospital, Southern Medical University, guangzhou, China
2 Nanfang Hospital, Southern Medical University, guangzhou, China
3 Nanfang Hospital, Southern Medical University, guangzhou, China
4 Nanfang Hospital, Southern Medical University, guangzhou, China
ABSTRACT
Background: AML1-ETO (AE) acute myeloid leukemia is traditionally classified as a favorable-risk subtype, yet its clinical relapse rate approaches 40%. The mechanisms underlying its response to venetoclax-based therapy remain poorly understood, and effective strategies to overcome resistance in this subtype are lacking.
Methods: We conducted a retrospective cohort study of 201 AML patients to evaluate treatment responses to IA chemotherapy and venetoclax combined with azacitidine (VA). Single-cell RNA sequencing was performed on bone marrow mononuclear cells from 26 AE and 52 non-AE AML patients to characterize leukemic heterogeneity and immune microenvironment composition. Mechanistic investigations were carried out using co-culture systems, western blotting, flow cytometry, high-throughput drug screening of 2,808 clinical compounds, and conditional knockout mouse models with mesenchymal stromal cell (MSC)-specific or endothelial cell (EC)-specific KITLG deletion to pinpoint the cellular source of resistance signals.
Results: Retrospective analysis revealed that AE AML patients had significantly lower response to VA compared to non-AE patients (CR/CRi 36.1% vs 79.4%, P<0.001), with higher MRD levels (5.44% vs 0%, P<0.001), while remaining sensitive to IA chemotherapy (90.7% vs 64.6%, P=0.001). Single-cell transcriptomics identified 12 leukemic clusters, revealing significant enrichment of primitive HSC-like subpopulations (C1/C2) characterized by mast cell signatures (TPSB2, RHEX, TPSAB1) and high KIT expression. These HSC-like cells displayed a unique anti-apoptotic protein profile with low BCL-2 and elevated BCL-XL expression. Immune microenvironment analysis uncovered increased mast cell infiltration in AE bone marrow with downregulated functional pathways and elevated VEGFA. Mechanistically, we demonstrated that bone marrow MSCs, but not ECs, secrete KITLG that binds to KIT receptors on AE cells, activating STAT3 phosphorylation and driving BCL-XL transcription. MSC-specific KITLG knockout in vivo abrogated venetoclax resistance, reducing peripheral blood leukemia burden and prolonging survival, while EC-specific knockout had no effect. High-throughput drug screening identified tyrosine kinase inhibitors as the most potent class against AE cells. The representative TKI sorafenib effectively blocked STAT3 phosphorylation, downregulated BCL-XL, and reversed MSC-induced venetoclax resistance in co-culture systems. In an AE AML mouse model, sorafenib combined with venetoclax significantly reduced leukemia burden and extended survival compared to either agent alone.
Conclusions: MSC-derived KITLG drives venetoclax resistance in AE AML through the KIT/STAT3/BCL-XL axis. Targeting this pathway with sorafenib restores venetoclax sensitivity and represents a promising therapeutic strategy for overcoming resistance in this high-risk AML subtype.
DISCLOSURES
Xi Jia: No relevant conflicts of interest to declare.